Back

Beta-blocker therapy and angina pectoris after myocardial infarction: a BETAMI-DANBLOCK substudy

23 April 2026 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award - Secondary Prevention and Rehabilitation Beta-Blockers Delegates Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Anna Meta Dyrvig Kristensen

Bispebjerg and Frederiksberg Hospital, Frederiksberg (Denmark)

3 More presentations in this session

Presentation thumbnail
Early post-discharge physical activity after myocardial infarction: safe and not linked to adverse outcomes
Mr R. Dijkman (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: a sub-study of the DANBLOCK-trial
Mrs F. Rykind Eriksen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Impact of different clinic models on cardiometabolic risk optimisation and cardioprotective therapies in post myocardial infarction patients with type 2 diabetes
Ms S. Alasmary (Leeds, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award - Secondary Prevention and Rehabilitation
Video

The Event

Event poster

ESC Preventive Cardiology 2026

23 April - 25 April 2026
You may be interested in
thumbnail
Webinar
Are beta-blockers still indicated after myocardial infarction?
thumbnail
Congress Presentation
Impact of beta-blocker therapy in patients with preserved left ventricular ejection fraction after ST-segment elevation myocardial infarction
thumbnail
Congress Presentation
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources